Logo image of CARM

CARISMA THERAPEUTICS INC (CARM) Stock Fundamental Analysis

NASDAQ:CARM - Nasdaq - US14216R1014 - Common Stock - Currency: USD

0.1759  -0.01 (-3.93%)

After market: 0.1731 0 (-1.59%)

Fundamental Rating

1

Overall CARM gets a fundamental rating of 1 out of 10. We evaluated CARM against 561 industry peers in the Biotechnology industry. Both the profitability and financial health of CARM have multiple concerns. CARM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CARM had negative earnings in the past year.
CARM had a negative operating cash flow in the past year.
CARM had negative earnings in each of the past 5 years.
CARM had negative operating cash flow in 4 of the past 5 years.
CARM Yearly Net Income VS EBIT VS OCF VS FCFCARM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -198.56%, CARM is doing worse than 90.37% of the companies in the same industry.
Industry RankSector Rank
ROA -198.56%
ROE N/A
ROIC N/A
ROA(3y)-102.03%
ROA(5y)-64.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CARM Yearly ROA, ROE, ROICCARM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CARM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CARM Yearly Profit, Operating, Gross MarginsCARM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

1

2. Health

2.1 Basic Checks

CARM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CARM has been increased compared to 1 year ago.
Compared to 5 years ago, CARM has more shares outstanding
Compared to 1 year ago, CARM has a worse debt to assets ratio.
CARM Yearly Shares OutstandingCARM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CARM Yearly Total Debt VS Total AssetsCARM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CARM has an Altman-Z score of -19.75. This is a bad value and indicates that CARM is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -19.75, CARM is not doing good in the industry: 86.45% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -19.75
ROIC/WACCN/A
WACC11.15%
CARM Yearly LT Debt VS Equity VS FCFCARM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.48 indicates that CARM should not have too much problems paying its short term obligations.
The Current ratio of CARM (1.48) is worse than 82.17% of its industry peers.
CARM has a Quick Ratio of 1.48. This is a normal value and indicates that CARM is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.48, CARM is doing worse than 81.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.48
Quick Ratio 1.48
CARM Yearly Current Assets VS Current LiabilitesCARM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

CARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.00%, which is quite impressive.
The Revenue has grown by 31.59% in the past year. This is a very strong growth!
CARM shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.56% yearly.
EPS 1Y (TTM)39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
Revenue 1Y (TTM)31.59%
Revenue growth 3Y-9.56%
Revenue growth 5YN/A
Sales Q2Q%9.77%

3.2 Future

The Earnings Per Share is expected to grow by 10.64% on average over the next years. This is quite good.
CARM is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y57.38%
EPS Next 2Y25.73%
EPS Next 3Y18.18%
EPS Next 5Y10.64%
Revenue Next Year-18.24%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CARM Yearly Revenue VS EstimatesCARM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 0 0 0 0 0
CARM Yearly EPS VS EstimatesCARM Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CARM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CARM Price Earnings VS Forward Price EarningsCARM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CARM Per share dataCARM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as CARM's earnings are expected to grow with 18.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.73%
EPS Next 3Y18.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CARM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARISMA THERAPEUTICS INC

NASDAQ:CARM (5/21/2025, 7:10:18 PM)

After market: 0.1731 0 (-1.59%)

0.1759

-0.01 (-3.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners33.66%
Inst Owner Change11.19%
Ins Owners1.19%
Ins Owner Change0%
Market Cap7.35M
Analysts77.78
Price Target1.02 (479.87%)
Short Float %0.96%
Short Ratio1.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-85.14%
Min EPS beat(2)-153.39%
Max EPS beat(2)-16.89%
EPS beat(4)1
Avg EPS beat(4)-40.88%
Min EPS beat(4)-153.39%
Max EPS beat(4)11.02%
EPS beat(8)4
Avg EPS beat(8)-30.02%
EPS beat(12)7
Avg EPS beat(12)10.51%
EPS beat(16)9
Avg EPS beat(16)25.25%
Revenue beat(2)0
Avg Revenue beat(2)-36.61%
Min Revenue beat(2)-39.29%
Max Revenue beat(2)-33.92%
Revenue beat(4)1
Avg Revenue beat(4)8.04%
Min Revenue beat(4)-39.29%
Max Revenue beat(4)129.7%
Revenue beat(8)4
Avg Revenue beat(8)62.78%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-84.62%
PT rev (3m)-84.62%
EPS NQ rev (1m)-20%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)-22%
EPS NY rev (3m)2.01%
Revenue NQ rev (1m)0.66%
Revenue NQ rev (3m)-20.05%
Revenue NY rev (1m)3.55%
Revenue NY rev (3m)-13.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.37
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.22
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.43
OCFYN/A
SpS0.47
BVpS-0.67
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -198.56%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-102.03%
ROA(5y)-64.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.64
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.67%
Cap/Sales 0.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.48
Quick Ratio 1.48
Altman-Z -19.75
F-Score4
WACC11.15%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.17%
EPS Next Y57.38%
EPS Next 2Y25.73%
EPS Next 3Y18.18%
EPS Next 5Y10.64%
Revenue 1Y (TTM)31.59%
Revenue growth 3Y-9.56%
Revenue growth 5YN/A
Sales Q2Q%9.77%
Revenue Next Year-18.24%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y29.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.19%
OCF growth 3YN/A
OCF growth 5YN/A